RT Journal Article SR Electronic T1 Delineating genetic and familial risk for psychopathology in the ABCD study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.09.08.20186908 DO 10.1101/2020.09.08.20186908 A1 C E Palmer A1 R Loughnan A1 C Makowski A1 W K Thompson A1 D Barch A1 T Jernigan A1 A Dale A1 C C Fan YR 2020 UL http://medrxiv.org/content/early/2020/09/10/2020.09.08.20186908.abstract AB ABSTRACTPsychiatric disorders place a huge burden on those affected and their families, as well as society. Nearly all psychiatric disorders have a heritable component and lifetime prevalence rates of several disorders are higher among first degree biological relatives of individuals with a diagnosis. Given that many psychiatric disorders have their onset in adolescence, estimating genetic risk during childhood may identify at-risk individuals for early intervention that can reduce this burden. Here we measured genetic risk for psychopathology using both polygenic risk scores (PRS) and family history in a large typically developing sample of 9-10 year old children from the Adolescent Brain and Cognitive Development (ABCD) StudySM and determined associations with a large battery of behavioural phenotypes. By including all genetic risk predictors in the same model, we were able to delineate unique behavioral associations across these measures. Polygenic risk for Attention Deficit Hyperactivity Disorder (ADHD) and depression (DEP) was associated with unique patterns of both externalizing and internalizing behaviors. Family history of conduct problems, depression and anxiety/stress additionally predicted unique behavioral variance across similar measures. These findings provide important insight into the potential predictive utility of PRS and family history in early adolescence and suggest that they may be signaling differential, additive information that could be useful for quantifying risk during development.Competing Interest StatementDr. Dale reports that he was a Founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc. He receives funding through research grants from GE Healthcare to UCSD. The terms of these arrangements have been reviewed by and approved by UCSD in accordance with its conflict of interest policies. Dr. Dale also reports that he has memberships with the following research consortia: Alzheimers Disease Genetics Consortium (ADGC); Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA); Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL); Psychiatric Genomics Consortium (PGC).Funding StatementData used in the preparation of this article were obtained from the Adolescent Brain Cognitive Development (ABCD) Study (https://abcdstudy.org), held in the NIMH Data Archive (NDA). The ABCD Study is supported by the National Institutes of Health and additional federal partners under award numbers U01DA041022, U01DA041028, U01DA041048, U01DA041089, U01DA041106, U01DA041117, U01DA041120, U01DA041134, U01DA041148, U01DA041156, U01DA041174, U24DA041123, U24DA041147, U01DA041093, and U01DA041025. R.L. was supported by the Kavli Innovative Research Grant (2019-1624) and C.F. was supported by a NIMH award (R01MH122688).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCSD IRB approved all data collection protocols for ABCD. IRB number: 160091. All analyses in this study used deidentified data, therefore no additional IRB approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available to download from the NIMH Data Archive ABCD Collection Release 2.0.1 (DOI: 10.15154/1504041).